alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2014409EN.01004401.xml

| 17.11.2014 | EN | Official Journal of the European Union | C 409/44 |
| --- | --- | --- | --- |

17.11.2014

EN

Official Journal of the European Union

C 409/44

---

Order of the President of the General Court of 18 September 2014 — Frucona Košice v Commission

(Case T-103/14 R II)

((Application for interim measures - State aid - Alcohol and spirits - Cancellation of a tax debt in a collective bankruptcy procedure - Decision declaring the aid incompatible with the internal market and ordering its recovery - Application for suspension of operation of a measure - Lack of any urgency - Prima facie case not made out))

2014/C 409/63

Language of the case: English

Parties

Parties

Applicant: Frucona Košice a.s., Košice (Slovakia), represented by K. Lasok QC, B. Hartnett and J. Holmes, Barristers, and O. Geiss, lawyer,

Applicant:

Defendant: European Commission (represented by: L. Armati, P. J. Loewenthal and K. Walkerová, acting as Agents)

Defendant:

Re:

Re:

Application for suspension of the operation of Commission Decision C(2013) 6261 final of 16 October 2013 on State aid SA.18211 (C 25/2005) (ex NN 21/2005), implemented by the Slovak Republic for Frucona Košice a.s., in so far as it orders the Slovak Republic to recover the aid.

Operative part of the order

Operative part of the order

| 1. | The application for interim measures is dismissed. |
| --- | --- |

1.

The application for interim measures is dismissed.

| 2. | Costs are reserved. |
| --- | --- |

2.

Costs are reserved.

---
Exhibit 15.1

LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION

Board of Directors and Shareholders

STERIS Corporation

We are aware of the incorporation by
reference in the following Registration Statements and related Prospectuses of our report dated November 7, 2008 relating to the unaudited consolidated interim financial statements of STERIS Corporation and subsidiaries that are included in its
Form 10-Q for the quarter ended September 30, 2008:



|                   |  |                                                                                                                      
|------------------ |  | ---------------------------------------------------------------------------------------------------------------------
|RegistrationNumber |  | Description                                                                                                          
|333-137167         |  | Form S-8 Registration Statement  STERIS Corporation Deferred Compensation Plan                                      
|                   | 
|333-136239         |  | Form S-8 Registration Statement  STERIS Corporation 2006 Long-Term Equity Incentive Plan                            
|                   | 
|333-65155          |  | Form S-8 Registration Statement  STERIS Corporation 1998 Long-Term Incentive Compensation Plan                      
|                   | 
|333-32005          |  | Form S-8 Registration Statement  STERIS Corporation 1997 Stock Option Plan                                          
|                   | 
|333-06529          |  | Form S-3 Registration Statement  STERIS Corporation                                                                 
|                   | 
|333-01610          |  | Post-effective Amendment to Form S-4 on Form S-8 Registration Statement  STERIS Corporation                         
|                   | 
|33-91444           |  | Form S-8 Registration Statement  STERIS Corporation 1994 Equity Compensation Plan                                   
|                   | 
|33-91442           |  | Form S-8 Registration Statement  STERIS Corporation 1994 Nonemployee Directors Equity Compensation Plan             
|                   | 
|33-55976           |  | Form S-8 Registration Statement  STERIS Corporation 401(k) Plan                                                     
|                   | 
|333-09733          |  | Form S-8 Registration Statement  STERIS Corporation 401(k) Plan                                                     
|                   | 
|333-101308         |  | Form S-8 Registration Statement  STERIS Corporation 2002 Stock Option Plan                                          
|                   | 
|333-91302          |  | Form S-8 Registration Statement  Nonqualified Stock Option Agreement between STERIS Corporation and Mark D. McGinley

/s/     ERNST & YOUNG
LLP

Cleveland, Ohio

November 7, 2008
Order entered September 16, 2016

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-16-01095-CV

IN RE: CC FORBES, LLC'S AND DEFENDANTS FORBES ENERGY SERVICES, LTD, 

FORBES ENERGY SERVICES DELAWARE, LLC, 

AND TX ENERGY SERVICES, LLC, Relators

Original proceeding from the 191st Judicial District Court

Dallas County, Texas

Trial Court Cause No. DC-14-12627

ORDER

Before the Court is relators’ September 15, 2016 emergency motion for temporary relief. 

We GRANT the motion and STAY the trial court’s September 12, 2016 order granting the 

motion to compel the depositions of John Crisp and Charles Forbes, Jr. Such stay shall remain in 

effect until further order of this Court. The Court further requests respondent and the real parties 

in interest to file their responses, if any, to relators’ September 15, 2016 petition for writ of 

mandamus by September 26, 2016.

/s/ BILL WHITEHILL

JUSTICE
#### § 70.55 Request for scientific studies.

The Commissioner will consider requests by any interested person who desires the Food and Drug Administration to conduct scientific studies to support a petition for a regulation for a color additive. If favorably acted upon, such studies will be limited to pharmacological investigations, studies of the chemical and physical structure of the color additive, and methods of analysis of the pure color additive (including impurities) and its identification and determination in foods, drugs, or cosmetics, as the case may be. All requests for such studies shall be accompanied by the fee prescribed in § 70.19.
Becky Schwantes - Questionnaire for the Steam Electric Power Generating Effluent Guidelines 

 

EPA is in the process of distributing the Questionnaire for the Steam Electric Power Generating Effluent 

Guidelines to selected fossil- and nuclear-fueled steam electric power plants. The questionnaire, which was 

approved by the Office of Management and Budget on May 20, 2010, can be viewed on EPA’s website at 

http://www.epa.gov/waterscience/guide/steam/. In addition, the website identifies the 733 facilities selected to 

receive the questionnaire. 

The questionnaire consists of nine sections which address specific processes, specific data needs, or types of 

power plants. It will collect general plant information and selected technical information about the plant processes 

and the electric generating units. The requested information includes economic data and technical information 

about flue gas desulfurization (FGD) wastewater, ash handling, cleaning of metal process equipment, wastewater 

treatment, surface impoundment and landfill operations, and nuclear operations. The questionnaire also requires 

certain power plants to collect and analyze samples of leachate from surface impoundments and landfills 

containing coal combustion residues. 

For further information about the questionnaire, please contact Ms. Jezebele Alicea-Virella by email at 

Alicea.Jezebele@epa.gov , or by telephone at (202) 566-1755. 

---------------------------------------------------------- 

Ron Jordan 

Engineering and Analysis Division (4303T) 

Office of Water 

U.S. Environmental Protection Agency 

1200 Pennsylvania Avenue, NW 

Washington, DC 20460 

(202) 566-1003 

http://www.epa.gov/waterscience

From: <Jordan.Ronald@epamail.epa.gov>

To:

 

<eschaeffer@environmentalintegrity.org>, <jpeterson@environmentalintegrity.org>, 

<craig.segall@sierraclub.org>, <akron@defenders.org>, <msenatore@defenders.org>, 

Abigail Dillen <adillen@earthjustice.org>

Date: 6/4/2010 7:30 PM

Subject: Questionnaire for the Steam Electric Power Generating Effluent Guidelines

CC: <Alicea.Jezebele@epamail.epa.gov>, <Reding.Richard@epamail.epa.gov>

Page 1 of 1

file://C:\Documents and Settings\BSchwantes\Local Settings\Temp\XPgrpwise\4C1912DC... 6/17/2010
§ 876.5220 Colonic irrigation system. ( a ) *Identification.* A colonic irrigation system is a device intended to instill water into the colon through a nozzle inserted into the rectum to cleanse (evacuate) the contents of the lower colon. The system is designed to allow evacuation of the contents of the colon during the administration of the colonic irrigation. The device consists of a container for fluid connected to the nozzle via tubing and includes a system which enables the pressure, temperature, or flow of water through the nozzle to be controlled. The device may include a console-type toilet and necessary fittings to allow the device to be connected to water and sewer pipes. The device may use electrical power to heat the water. The device does not include the enema kit (§ 876.5210).
( b ) *Classification.* ( 1 ) Class II (performance standards) when the device is intended for colon cleansing when medically indicated, such as before radiological or endoscopic examinations.
( 2 ) Class III (premarket approval) when the device is intended for other uses, including colon cleansing routinely for general well being.
( c ) *Date PMA or notice of completion of a PDP is required.* A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any colonic irrigation system described in paragraph (b)(2) of this section that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a colonic irrigation system described in paragraph (b)(2) of this section that was in commercial distribution before May 28, 1976. Any other colonic irrigation system shall have an approved PMA in effect before being placed in commercial distribution.
[48 FR 53023, Nov. 23, 1983, as amended at 52 FR 17738, May 11, 1987; 61 FR 50707, Sept. 27, 1996]
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Gold, SDR's, and Central Bank Swaps

              																	United States. Congress. Joint Economic Committee. Subcommittee on International Exchange and Payments					 and 	Ninety-Second Congress, 1971-1973. 						*Gold, SDR's, and Central Bank Swaps : Report of the Subcommittee on International Exchange and Payments of the Joint Economic Committee, Congress of the United States*,												Washington: 								U.S. Government Printing Office, 										November 18, 1972,									https://fraser.stlouisfed.org/title/886,			accessed on September 22, 2024.						    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
# C_2015065EN.01005002.xml

| 23.2.2015 | EN | Official Journal of the European Union | C 65/50 |
| --- | --- | --- | --- |

23.2.2015

EN

Official Journal of the European Union

C 65/50

---

Action brought on 22 December 2014 — Airpressure Bodyforming v OHIM (Slim legs by airpressure bodyforming)

(Case T-842/14)

(2015/C 065/68)

Language of the case: German

Parties

Parties

Applicant: Airpressure Bodyforming GmbH (Berchtesgaden, Germany) (represented by: S. Merz, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM)

Defendant:

Details of the proceedings before OHIM

Details of the proceedings before OHIM

Trade mark at issue: Community word mark ‘Slim legs by airpressure bodyforming’ — Application No 12 533 709

Trade mark at issue:

Contested decision: Decision of the Fifth Board of Appeal of OHIM of 29 October 2014 in Case R 1570/2014-5

Contested decision

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | annul the contested decision; |
| --- | --- |

—

annul the contested decision;

| — | order OHIM to pay the costs. |
| --- | --- |

—

order OHIM to pay the costs.

Pleas in law

Pleas in law

| — | Infringement of Article 7(1)(c) of Regulation No 207/2009; |
| --- | --- |

—

Infringement of Article 7(1)(c) of Regulation No 207/2009;

| — | Infringement of Article 7(1)(b) of Regulation No 207/2009. |
| --- | --- |

—

Infringement of Article 7(1)(b) of Regulation No 207/2009.

---
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.1390 Flexible diagnostic Fresnel lens. ( a ) *Identification.* A flexible diagnostic Fresnel lens is a device that is a very thin lens which has its surface a concentric series of increasingly refractive zones. The device is intended to be applied to the back of the spectacle lenses of patients with aphakia (absence of the lens of the eye).
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 886.9. The device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[52 FR 33355, Sept. 2, 1987, as amended at 53 FR 35604, Sept. 14, 1988; 66 FR 38811, July 25, 2001]
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Noninvasive Imaging of Beta Cells.                    

*Date:*                         March 24, 2010.                    

*Time:*                         3 p.m. to 4 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).                    

*Contact Person:*                         Paul A. Rushing, PhD, Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 747, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-8895,                         *rushingp@extra.niddk.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: February 23, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-4181 Filed 2-26-10; 8:45 am]

BILLING CODE 4140-01-P
#### § 357.210 Cholecystokinetic active ingredients.

The active ingredient of the product consists of any of the following when used within the specified concentration and dosage form established for each ingredient:

(a) 50-percent aqueous emulsion of corn oil.

(b) Hydrogenated soybean oil in a suitable, water-dispersible powder. The hydrogenated soybean oil is food-grade, partially hydrogenated with a melting point of 41 to 43.5 °C, an iodine value of 65 to 69, and a fatty acid composition as follows:

| Fatty acid | Percent composition |
| --- | --- |
| Myristic acid | 0.1 |
| Palmitic acid | 10.0 |
| Palmitoleic acid | 0.1 |
| Stearic acid | 13.5 |
| Oleic acid | 72.0 |
| Linoleic acid | 3.8 |
| Linolenic acid | 0.1 |
| Arachidic acid | 0.5 |
| Behenic acid | 0.2 |

[54 FR 8321, Feb. 28, 1989]
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Federal Retirement Thrift Investment Board

# Time and Date:

9 a.m. (Eastern Time) March 15, 2010.

# Place:

4th Floor Conference Room, 1250 H Street, NW., Washington, DC 20005.

# Status:

Parts will be open to the public and parts closed to the public.

# Matters to be Considered

 

## Parts Open to the Public

1. Approval of the minutes of the February 16, 2010, Board member meeting.

2. Thrift Savings Plan activity report by the Executive Director.

a. Monthly Participant Activity Report.

b. Monthly Investment Performance Report.

c. Legislative Report.

## Parts Closed to the Public

3. Proprietary Data.

4. Proprietary Data.

# Contact Person for More Information:

Thomas J. Trabucco, Director, Office of External Affairs, (202) 942-1640.

Dated: March 4, 2010.

Thomas K. Emswiler,

Secretary, Federal Retirement Thrift Investment Board.

[FR Doc. 2010-5049 Filed 3-5-10; 11:15 am]

BILLING CODE 6760-01-P
# C_2015073EN.01003901.xml

| 2.3.2015 | EN | Official Journal of the European Union | C 73/39 |
| --- | --- | --- | --- |

2.3.2015

EN

Official Journal of the European Union

C 73/39

---

Action brought on 24 November 2014 — Red Lemon v OHIM — Lidl Stiftung (ABTRONIC)

(Case T-775/14)

(2015/C 073/50)

Language in which the application was lodged: German

Parties

Applicant: Red Lemon Inc. (Hong Kong, China) (represented by: T. Wieland and S. Müller, lawyers)

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM)

Other party to the proceedings before the Board of Appeal: Lidl Stiftung & Co. KG (Neckarsulm, Germany)

Details of the proceedings before OHIM

Applicant for the trade mark at issue: the applicant

Trade mark at issue: Community figurative mark including the word element ‘ABTRONIC’ — Application No 8 534 811

Procedure before OHIM: Opposition proceedings

Contested decision: Decision of the First Board of Appeal of OHIM of 4 September 2014 in Case R 2060/2013-1

Form of order sought

The applicant claims that the Court should:

| — | annul the contested decision and reject the opposition; |
| --- | --- |

—

annul the contested decision and reject the opposition;

| — | order OHIM to pay the costs. |
| --- | --- |

—

order OHIM to pay the costs.

Plea in law

Infringement of 8(1)(b) of Regulation No 207/2009.

---
Exhibit 32.1



Certification Pursuant to § 906 of the Sarbanes-Oxley Act of 2002



Pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, in connection with
the filing of the Form 10-Q/A of STERIS Corporation for the quarter ended September 30, 2004, as filed with the Securities and Exchange Commission on the date hereof (the Report), each of the undersigned officers of the Company
certifies, that, to such officers knowledge:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the
periods expressed in the Report.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



A signed
original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section
906, has been provided to STERIS Corporation and will be retained by STERIS Corporation and furnished to the Securities and Exchange Commission or its staff upon request.



/s/ Les C. VinneyName:

Les C. VinneyTitle:

President and Chief Executive Officer/s/ Laurie BrlasName:

Laurie BrlasTitle:

Senior Vice President and Chief Financial Officer




Dated: November 18, 2004